South Korea · Delayed Price · Currency is KRW Tdspharm Statistics
Total Valuation
Tdspharm has a market cap or net worth of KRW 35.61 billion. The enterprise value is 21.22 billion.
| Market Cap | 35.61B |
| Enterprise Value | 21.22B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Tdspharm has 5.53 million shares outstanding. The number of shares has increased by 7.95% in one year.
| Current Share Class | 5.53M |
| Shares Outstanding | 5.53M |
| Shares Change (YoY) | +7.95% |
| Shares Change (QoQ) | -0.11% |
| Owned by Insiders (%) | 46.44% |
| Owned by Institutions (%) | 4.27% |
| Float | 2.94M |
Valuation Ratios
The trailing PE ratio is 6.73.
| PE Ratio | 6.73 |
| Forward PE | n/a |
| PS Ratio | 1.17 |
| PB Ratio | 0.81 |
| P/TBV Ratio | 0.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 7.20 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 4.20 |
| EV / Sales | 0.70 |
| EV / EBITDA | 3.77 |
| EV / EBIT | 4.31 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.09, with a Debt / Equity ratio of 0.32.
| Current Ratio | 2.09 |
| Quick Ratio | 1.89 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | 2.47 |
| Debt / FCF | -1.68 |
| Interest Coverage | 19.71 |
Financial Efficiency
Return on equity (ROE) is 12.21% and return on invested capital (ROIC) is 13.83%.
| Return on Equity (ROE) | 12.21% |
| Return on Assets (ROA) | 5.56% |
| Return on Invested Capital (ROIC) | 13.83% |
| Return on Capital Employed (ROCE) | 11.16% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.55 |
| Inventory Turnover | 7.31 |
Taxes
In the past 12 months, Tdspharm has paid 956.62 million in taxes.
| Income Tax | 956.62M |
| Effective Tax Rate | 15.91% |
Stock Price Statistics
The stock price has decreased by -45.24% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -45.24% |
| 50-Day Moving Average | 8,237.60 |
| 200-Day Moving Average | 9,338.70 |
| Relative Strength Index (RSI) | 27.12 |
| Average Volume (20 Days) | 32,911 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Tdspharm had revenue of KRW 30.41 billion and earned 5.05 billion in profits. Earnings per share was 956.97.
| Revenue | 30.41B |
| Gross Profit | 8.59B |
| Operating Income | 4.92B |
| Pretax Income | 6.01B |
| Net Income | 5.05B |
| EBITDA | 5.63B |
| EBIT | 4.92B |
| Earnings Per Share (EPS) | 956.97 |
Balance Sheet
The company has 28.30 billion in cash and 13.90 billion in debt, with a net cash position of 14.39 billion or 2,602.81 per share.
| Cash & Cash Equivalents | 28.30B |
| Total Debt | 13.90B |
| Net Cash | 14.39B |
| Net Cash Per Share | 2,602.81 |
| Equity (Book Value) | 43.93B |
| Book Value Per Share | 8,315.92 |
| Working Capital | 19.53B |
Cash Flow
In the last 12 months, operating cash flow was 4.94 billion and capital expenditures -13.24 billion, giving a free cash flow of -8.30 billion.
| Operating Cash Flow | 4.94B |
| Capital Expenditures | -13.24B |
| Depreciation & Amortization | 708.99M |
| Net Borrowing | 7.25B |
| Free Cash Flow | -8.30B |
| FCF Per Share | -1,500.53 |
Margins
Gross margin is 28.24%, with operating and profit margins of 16.18% and 16.62%.
| Gross Margin | 28.24% |
| Operating Margin | 16.18% |
| Pretax Margin | 19.77% |
| Profit Margin | 16.62% |
| EBITDA Margin | 18.51% |
| EBIT Margin | 16.18% |
| FCF Margin | n/a |
Dividends & Yields
Tdspharm does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.95% |
| Shareholder Yield | -7.95% |
| Earnings Yield | 14.19% |
| FCF Yield | -23.30% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Tdspharm has an Altman Z-Score of 3.97 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.97 |
| Piotroski F-Score | 4 |